Company / Income Tax
ALNYLAM PHARMACEUTICALS, INC. Income Tax History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Income Tax
$9.4M
FY2025
5-year range
-$99.2M / $9.4M
FY2021-FY2025
Trend
+109.5%
vs FY2024
Sector context
#48 of 204
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s income tax of $9M is higher than 76% of companies in the Health Care sector (FY2025). Increased from $7M to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +62.8%. Top quartile in the Health Care sector.
Increased from $7M to $9M over the past 2 years.
Health Care sector context is included.
Income Tax over time
Growth rates
- 3-Year CAGR
- +51.9%
- 5-Year CAGR
- +62.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 204This company $9.4M Sector average $118.7M
▼
-92.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +62.8%, indicating consistent growth.
- In FY2025, income tax increased 109.5% year-over-year.
- Ranks #48 out of 204 companies in the Health Care sector.
- Lowest income tax in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Income TaxValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.4M | +109.5% |
| FY2024 | -$99.2M | -1575.4% |
| FY2023 | $6.7M | +150.8% |
| FY2022 | $2.7M | +210.7% |
| FY2021 | $863.0K | +4.9% |
| FY2020 | $823.0K | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | $0 | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026